×
S&P 500   3,835.36 (+0.10%)
DOW   30,994.30 (+0.09%)
QQQ   286.80 (-0.06%)
AAPL   141.78 (+0.16%)
MSFT   263.65 (+0.30%)
META   166.24 (-1.16%)
GOOGL   2,244.18 (-0.93%)
AMZN   112.67 (-0.73%)
TSLA   685.43 (-1.97%)
NVDA   148.89 (-0.50%)
NIO   20.97 (-5.46%)
BABA   116.00 (-3.44%)
AMD   74.16 (-1.38%)
MU   57.17 (+0.78%)
CGC   2.60 (-4.06%)
T   21.14 (-0.14%)
GE   61.72 (-0.50%)
F   10.85 (-3.13%)
DIS   96.71 (-0.48%)
AMC   12.62 (-1.25%)
PFE   52.55 (+1.76%)
PYPL   73.57 (-1.12%)
NFLX   181.53 (-2.34%)
S&P 500   3,835.36 (+0.10%)
DOW   30,994.30 (+0.09%)
QQQ   286.80 (-0.06%)
AAPL   141.78 (+0.16%)
MSFT   263.65 (+0.30%)
META   166.24 (-1.16%)
GOOGL   2,244.18 (-0.93%)
AMZN   112.67 (-0.73%)
TSLA   685.43 (-1.97%)
NVDA   148.89 (-0.50%)
NIO   20.97 (-5.46%)
BABA   116.00 (-3.44%)
AMD   74.16 (-1.38%)
MU   57.17 (+0.78%)
CGC   2.60 (-4.06%)
T   21.14 (-0.14%)
GE   61.72 (-0.50%)
F   10.85 (-3.13%)
DIS   96.71 (-0.48%)
AMC   12.62 (-1.25%)
PFE   52.55 (+1.76%)
PYPL   73.57 (-1.12%)
NFLX   181.53 (-2.34%)
S&P 500   3,835.36 (+0.10%)
DOW   30,994.30 (+0.09%)
QQQ   286.80 (-0.06%)
AAPL   141.78 (+0.16%)
MSFT   263.65 (+0.30%)
META   166.24 (-1.16%)
GOOGL   2,244.18 (-0.93%)
AMZN   112.67 (-0.73%)
TSLA   685.43 (-1.97%)
NVDA   148.89 (-0.50%)
NIO   20.97 (-5.46%)
BABA   116.00 (-3.44%)
AMD   74.16 (-1.38%)
MU   57.17 (+0.78%)
CGC   2.60 (-4.06%)
T   21.14 (-0.14%)
GE   61.72 (-0.50%)
F   10.85 (-3.13%)
DIS   96.71 (-0.48%)
AMC   12.62 (-1.25%)
PFE   52.55 (+1.76%)
PYPL   73.57 (-1.12%)
NFLX   181.53 (-2.34%)
S&P 500   3,835.36 (+0.10%)
DOW   30,994.30 (+0.09%)
QQQ   286.80 (-0.06%)
AAPL   141.78 (+0.16%)
MSFT   263.65 (+0.30%)
META   166.24 (-1.16%)
GOOGL   2,244.18 (-0.93%)
AMZN   112.67 (-0.73%)
TSLA   685.43 (-1.97%)
NVDA   148.89 (-0.50%)
NIO   20.97 (-5.46%)
BABA   116.00 (-3.44%)
AMD   74.16 (-1.38%)
MU   57.17 (+0.78%)
CGC   2.60 (-4.06%)
T   21.14 (-0.14%)
GE   61.72 (-0.50%)
F   10.85 (-3.13%)
DIS   96.71 (-0.48%)
AMC   12.62 (-1.25%)
PFE   52.55 (+1.76%)
PYPL   73.57 (-1.12%)
NFLX   181.53 (-2.34%)
NASDAQ:ACAD

ACADIA Pharmaceuticals Price Target, Predictions & Analyst Ratings

$15.40
+0.13 (+0.85%)
(As of 07/6/2022 09:53 AM ET)
Add
Compare
Today's Range
$15.17
$15.56
50-Day Range
$13.01
$19.89
52-Week Range
$12.24
$28.06
Volume
7,492 shs
Average Volume
4.40 million shs
Market Capitalization
$2.49 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.63

ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target and Consensus Rating (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 18 Analyst Ratings

Consensus Analyst Price Target

$24.63
59.94% Upside
High Prediction$35.00
Average Prediction$24.63
Low Prediction$10.00
TypeCurrent
7/6/21 to 7/6/22
1 Month Ago
6/6/21 to 6/6/22
3 Months Ago
4/7/21 to 4/7/22
1 Year Ago
7/6/20 to 7/6/21
Consensus Rating
Hold
Moderate Buy
Moderate Buy
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
6 Buy rating(s)
Hold
8 Hold rating(s)
8 Hold rating(s)
9 Hold rating(s)
11 Hold rating(s)
Sell
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$24.63$29.45$29.04$31.40
Predicted Upside59.94% Upside22.93% Upside21.52% Upside13.80% Upside
Get ACADIA Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter.


ACAD Stock Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ACAD Stock Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

ACADIA Pharmaceuticals Stock vs. The Competition

TypeACADIA PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.44
2.72
2.51
Consensus RatingHoldBuyBuy
Predicted Upside61.30% Upside458.51% Upside31.80% Upside
News Sentiment RatingNeutral News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
824
76.16%
Underperform Votes
258
23.84%
Avg. Outperform Votes
167
67.07%
Avg. Underperform Votes
82
32.93%
Avg. Outperform Votes
840
69.14%
Avg. Underperform Votes
375
30.86%

Historical ACADIA Pharmaceuticals Price Targets and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/22/2022Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Sumant Kulkarni
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Target$31.00 ➝ $20.00+57.98%
6/22/2022Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Neena Bitritto-Garg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy$32.00 ➝ $19.00+46.04%
6/21/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Neutral
6/21/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Underperform$25.00 ➝ $10.00-23.02%
6/21/2022Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$32.00 ➝ $26.00+107.67%
6/21/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Perform$23.00 ➝ $19.00+51.76%
6/21/2022Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$37.00 ➝ $26.00+33.26%
6/21/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Fein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy$36.00 ➝ $20.00+2.51%
4/19/2022Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$28.00 ➝ $27.00+20.48%
3/18/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jeffrey Hung
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold$24.00-5.44%
3/7/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$27.00 ➝ $24.00-1.84%
3/1/2022JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jason Butler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetMarket Outperform$42.00 ➝ $35.00+37.74%
12/23/2021SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Goodman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
12/21/2021Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$28.00 ➝ $32.00+46.79%
12/21/2021Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$28.00+3.36%
8/5/2021Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$30.00 ➝ $26.00+28.14%
7/10/2021Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Set Target$23.71
6/10/2021Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$29.00+10.98%
3/15/2021Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold$68.00 ➝ $27.00-0.15%
3/9/2021Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$66.00 ➝ $57.00+24.51%
9/9/2019Piper Jaffray Companies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$35.00 ➝ $56.00+44.14%
(Data available from 7/6/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ACADIA Pharmaceuticals Price Target - Frequently Asked Questions

What is ACADIA Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 18 analysts in the last year, the consensus rating for ACADIA Pharmaceuticals stock is Hold based on the current 1 sell rating, 8 hold ratings and 9 buy ratings for ACAD. The average twelve-month price prediction for ACADIA Pharmaceuticals is $24.63 with a high price target of $35.00 and a low price target of $10.00. Learn more on ACAD's analyst rating history.

Do Wall Street analysts like ACADIA Pharmaceuticals more than its competitors?

Analysts like ACADIA Pharmaceuticals stock less than the stock of other Medical companies. The consensus rating for ACADIA Pharmaceuticals is Hold while the average consensus rating for medical companies is Buy. Learn more on how ACAD compares to other companies.

Do MarketBeat users like ACADIA Pharmaceuticals more than its competitors?

MarketBeat users like ACADIA Pharmaceuticals stock more than the stock of other Medical companies. 76.16% of MarketBeat users gave ACADIA Pharmaceuticals an outperform vote while medical companies recieve an average of 66.80% outperform votes by MarketBeat users.

Is ACADIA Pharmaceuticals being upgraded or downgraded by Wall Street analysts?

Over the previous 90 days, ACADIA Pharmaceuticals's stock had 2 downgrades and 1 upgrade by analysts.

Does ACADIA Pharmaceuticals's stock price have much upside?

According to analysts, ACADIA Pharmaceuticals's stock has a predicted upside of 23.08% based on their 12-month price targets.

What analysts cover ACADIA Pharmaceuticals?
This page (NASDAQ:ACAD) was last updated on 7/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.